CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Curis, Inc.
Pfizer
Amgen
Lyell Immunopharma, Inc.
BeOne Medicines
Genmab
Janssen Research & Development, LLC
Regeneron Pharmaceuticals
Beijing Biotech
Gilead Sciences
Otsuka Pharmaceutical Co., Ltd.
Autolus Limited
Bristol-Myers Squibb
SecuraBio
AstraZeneca
Novartis
Takeda
Hoffmann-La Roche
Prescient Therapeutics, Ltd.
Amgen
AbbVie
Pfizer
AstraZeneca
Treeline Biosciences, Inc.
C4 Therapeutics, Inc.
Sumitomo Pharma America, Inc.
Novartis
MSD R&D (China) Co., Ltd.
Cellectar Biosciences, Inc.
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Sellas Life Sciences Group
Gilead Sciences
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Allogene Therapeutics
Allogene Therapeutics
Allogene Therapeutics
Autolus Limited
Otsuka Pharmaceutical Co., Ltd.
AstraZeneca
Ascentage Pharma Group Inc.
Celgene
Ono Pharmaceutical Co. Ltd
Merck Sharp & Dohme LLC
PeproMene Bio, Inc.
Arvinas Inc.
Regeneron Pharmaceuticals
Chengdu Zenitar Biomedical Technology Co., Ltd
Excyte Biopharma Ltd
SymBio Pharmaceuticals
BIOHENG THERAPEUTICS US LLC